Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 44: 924-929, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (37)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pastor, M-C.
Right arrow Articles by Serés, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pastor, M-C.
Right arrow Articles by Serés, A.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Nutrition
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1998;44:924-929.)
© 1998 American Association for Clinical Chemistry, Inc.


Enzymes and Protein Markers

Antioxidant enzymes and fatty acid status in erythrocytes of Down syndrome patients

M-Cruz Pastor1,a, Cristina Sierra2, María Doladé1, Elisabet Navarro1, Nuria Brandi2, Eduard Cabré1, Aurea Mira2, and Agustí Serés3

1 Hospital Universitario Germas Trias i Pujol, 08915 Badalona, Spain.

2 Hospital San Juan de Dios, 08950 Barcelona, Spain.

3 Fundació Catalana Sindrome de Down, Barcelona, Spain.
a Address correspondence to this author at: Servicio de Bioquímica, Hospital Universitario Germans Trias i Pujol, Ctra del canyet s/n, 08915 Badalona, Spain. Fax 34-3-395 42 06.

The excess of genetic information in patients with Down syndrome (DS) produces an increase in the catalytic activity of superoxide dismutase (SOD1), an antioxidant enzyme coded on chromosome 21. It has been suggested that an increase in oxidative stress in DS patients may cause adverse effects in the cell membranes through the oxidation of polyunsaturated fatty acids (PUFAs). The aim of this study was to evaluate the cellular antioxidant system by determining the catalytic activity of the SOD1, glutathione peroxidase (GPx), catalase (CAT), and glutathione reductase (GR) enzymes and the concentrations of {alpha}-tocopherol in red blood cells (RBCs) in a group of 72 DS patients. The profile of fatty acids in the phospholipids of RBC membranes was also evaluated. The activity of the erythrocyte antioxidant enzymes is significantly higher in the DS group than in the control group (SOD1, 635 ± 70 U/g Hb vs 476 ± 67 U/g Hb; CAT, 1843 ± 250 U/g Hb vs 1482 ± 250 U/g Hb; GPx, 23.2 ± 5.3 U/g Hb vs 21.5 ± 3.6 U/g Hb; and GR, 9.32 ± 1.4 U/g Hb vs 6.9 ± 1.3 U/g Hb, respectively). No differences were observed in RBC {alpha}-tocopherol concentrations between the two groups studied. Long-chain n6 PUFA (C20:3n6, C20:4n6) concentrations were increased in DS patients, suggesting enhanced {Delta}-6-desaturase activity. The long-chain n3 PUFA (docosahexenoic acid) does not appear to be affected by increased oxidative stress, probably because of the existence of compensatory antioxidant mechanisms.




The following articles in journals at HighWire Press have cited this article:


Home page
Mayo Clin Proc.Home page
M. E. Garcez, W. Peres, and M. Salvador
Oxidative Stress and Hematologic and Biochemical Parameters in Individuals With Down Syndrome
Mayo Clin. Proc., December 1, 2005; 80(12): 1607 - 1611.
[Abstract] [PDF]


Home page
Arch. Dis. Child.Home page
G Tozzi, M Nuccetelli, M Lo Bello, S Bernardini, L Bellincampi, S Ballerini, L M Gaeta, C Casali, A Pastore, G Federici, et al.
Antioxidant enzymes in blood of patients with Friedreich's ataxia
Arch. Dis. Child., May 1, 2002; 86(5): 376 - 379.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.